Allarity Therapeutics (ALLR) Common Equity (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Common Equity came in at $6.9 million in Q1 2026, down 62.93% YoY from $18.7 million in Q1 2025, and down 29.59% on a QoQ basis from $9.8 million in Q4 2025.
Allarity Therapeutics (ALLR) Common Equity (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Common Equity data on file, last reported at $6.9 million in Q1 2026.
- Quarterly Common Equity fell 62.93% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (down 62.93% YoY) and the FY2025 annual result came in at $9.8 million, down 16.79% from the prior year.
- Common Equity retreated to $6.9 million in Q1 2026, from $9.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $19.8 million in Q2 2024 to a low of -$6.5 million in Q1 2024.
- A 5-year average of $6.6 million and a median of $8.0 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity sank 2334.51% — and 2024, when it surged 2843.43%.
- Tracing ALLR's Common Equity over 5 years: stood at -$113000.0 in 2022, then slumped by 2334.51% to -$2.8 million in 2023, then soared by 529.33% to $11.8 million in 2024, then dropped by 16.79% to $9.8 million in 2025, then slipped by 29.59% to $6.9 million in 2026.
- The last three Common Equity figures came in at $6.9 million (Q1 2026), $9.8 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Allarity Therapeutics | 23.23 Mn | 23.23 Mn | - | 3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.92 Mn |
| Dec 31, 2025 | 9.83 Mn |
| Sep 30, 2025 | 12.01 Mn |
| Jun 30, 2025 | 12.17 Mn |
| Mar 31, 2025 | 18.67 Mn |
| Dec 31, 2024 | 11.81 Mn |
| Sep 30, 2024 | 12.96 Mn |
| Jun 30, 2024 | 19.84 Mn |
| Mar 31, 2024 | -6.47 Mn |
| Dec 31, 2023 | -2.75 Mn |
| Sep 30, 2023 | -3.38 Mn |
| Jun 30, 2023 | -723,000.00 |
| Mar 31, 2023 | -3.10 Mn |
| Dec 31, 2022 | -113,000.00 |
| Sep 30, 2022 | 1.45 Mn |
| Jun 30, 2022 | 7.97 Mn |
| Mar 31, 2022 | 14.73 Mn |
| Dec 31, 2021 | 18.15 Mn |
| Sep 30, 2021 | 29.66 Mn |
| Jun 30, 2021 | 28.82 Mn |